EyePoint Pharmaceuticals (EYPT) Research & Development: 2010-2018
Historic Research & Development for EyePoint Pharmaceuticals (EYPT) over the last 9 years, with Jun 2018 value amounting to $16.2 million.
- EyePoint Pharmaceuticals' Research & Development rose 63.21% to $6.2 million in Q3 2018 from the same period last year, while for Sep 2018 it was $18.6 million, marking a year-over-year increase of 28.04%. This contributed to the annual value of $16.2 million for FY2018, which is 8.72% up from last year.
- Latest data reveals that EyePoint Pharmaceuticals reported Research & Development of $16.2 million as of FY2018, which was up 8.72% from $14.9 million recorded in FY2017.
- EyePoint Pharmaceuticals' 5-year Research & Development high stood at $16.2 million for FY2018, and its period low was $9.6 million during FY2014.
- Moreover, its 3-year median value for Research & Development was $14.9 million (2017), whereas its average is $15.1 million.
- Data for EyePoint Pharmaceuticals' Research & Development shows a peak YoY skyrocketed of 36.66% (in 2014) over the last 5 years.
- Over the past 5 years, EyePoint Pharmaceuticals' Research & Development (Yearly) stood at $9.6 million in 2014, then grew by 26.27% to $12.1 million in 2015, then grew by 18.97% to $14.4 million in 2016, then rose by 3.47% to $14.9 million in 2017, then increased by 8.72% to $16.2 million in 2018.